Skip to main content

Laura Conesa Milian

Institutions of which they are part

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Laura Conesa Milian

Institutions of which they are part

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Creación de un método de referencia para detectar Apo-lb por espectrometría de masas dirigida y validación clínica de su potencial como biomarcadore para el síndrome nefrótico idiopático

IP: Concepció Jacobs Cachá
Collaborators: Laura Conesa Milian, Yolanda Villena Ortiz, Joan López Hellin, Carmen Llorens Cebriá, Juan Carlos León Román
Funding agency: Instituto de Salud Carlos III
Funding: 71250
Reference: PI24/01573
Duration: 01/01/2025 - 31/12/2027

Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT)

IP: -
Collaborators: José Antonio Arranz Amo, Raquel Barquin Del Pino, Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Pablo Gabriel Medina, Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Maria Francesca Cortese, Sandra Mancilla Zamora
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 01173
Duration: 01/01/2022 - 30/06/2025

Related news

The annual event offered a space for dialogue between the scientific community and society on how to address the future of ageing through research and innovation.

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Related professionals

Victoria López Craver

Victoria López Craver

Psychiatry, Mental Health and Addictions
Read more
Laura Roman Pons

Laura Roman Pons

Research technician
Clinical Neuroimmunology
Read more
Laia Aceituno Sierra

Laia Aceituno Sierra

Predoctoral researcher
Liver Diseases
Read more
Montserrat García Portabella

Montserrat García Portabella

Reconstructive Surgery of the Locomotor System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.